Ashley E. Ross, MD, PhD, presented “Considerations for the Clinical Impact of Next Generation Imaging in Prostate Cancer” during The 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 3, 2019 in Boston, Massachusetts.

How to cite: Ross, Ashley E. “Considerations for the Clinical Impact of Next Generation Imaging in Prostate Cancer” October 3, 2019. Accessed Mar 2024. https://grandroundsinurology.com/considerations-for-the-clinical-impact-of-next-generation-imaging-in-prostate-cancer/

Considerations for the Clinical Impact of Next Generation Imaging in Prostate Cancer – Summary:

Ashley E. Ross, MD, PhD, Executive Medical Director of the Mary Crowley Cancer Research Center in Dallas, discusses the current and potential impact of PSMA PET imaging on the identification and treatment of localized prostate cancer. He notes how PET PSMA and fluciclovine imaging can increase the accuracy of detecting clinically significant localized disease. Dr. Ross further discusses how PET imaging assists in risk stratification of candidates for treatment of HSPC, nmCRPC using salvage local therapy, metastasis-directed therapy, or intensification of systemic therapy. He also discusses how PET imaging can help identify candidates for cure with local treatments.

About The 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer:

The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a multi-day, multi-disciplinary forum designated to informing health care stakeholders about topics including in-vitro fluid- and tissue-based molecular diagnostics, novel observation strategies such as active surveillance, and novel therapeutic interventions. Along with this forum’s efforts to form a consensus on the future of prostate diagnostics and precision care, it aims to create an educational and research strategy for its realization. Dr. Ross presented this lecture during the 4th iteration of this Summit in 2019.